Gonadorelin (2mg)
Gonadorelin dosing supports the restoration of natural LH and FSH release from the pituitary gland by reactivating the hypothalamic-pituitary-gonadal (HPG) axis. As a synthetic form of gonadotropin-releasing hormone (GnRH), gonadorelin stimulates testosterone production in men and promotes ovulation in women when administered in short, pulsatile doses. This protocol outlines a subcutaneous microdosing approach.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Gonadorelin is a synthetic decapeptide identical to the endogenous gonadotropin-releasing hormone (GnRH) secreted by the hypothalamus. When administered in a short, pulsatile fashion, it binds to GnRH receptors on pituitary gonadotroph cells, triggering the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates Leydig cells to produce testosterone in men and triggers ovulation in women, while FSH supports spermatogenesis and follicular development. Unlike continuous administration of GnRH agonists, which desensitizes receptors, short intermittent dosing preserves the natural pulsatile signaling pattern.
Quick Start
- Reconstitution: Add 2.0 mL of bacteriostatic water → 1 mg/mL (1000 mcg/mL) concentration.
- Typical Dose Range: 50–250 mcg per injection, 2–3 times weekly.
- Storage: Lyophilized: −20 °C; post-reconstitution, refrigerate at 2–8 °C; avoid freeze-thaw cycles.
Typical / Maintenance Approach (2 mL = 1 mg/mL)
Route: Subcutaneous | Frequency: 2–3 times weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 (Initiation) | 50 mcg | 5 Units (0.05 mL) |
| Weeks 3–4 (Titration) | 100 mcg | 10 Units (0.10 mL) |
| Weeks 5–8 (Maintenance) | 100–150 mcg | 10–15 Units (0.10–0.15 mL) |
Studies report administration 2–3 times weekly subcutaneously on non-consecutive days (e.g., Mon/Wed/Fri).
Related compounds
Reconstitution Steps
- Withdraw 2.0 mL of bacteriostatic water.
- Inject slowly down the side; avoid foaming.
- Gently swirl/rotate until dissolved (do not shake).
- Note concentration (1 mg/mL) and date; refrigerate at 2–8 °C.
Protocol Overview
- Objective: Stimulate endogenous LH and FSH release to support testosterone production and testicular function.
- Schedule: Subcutaneous injections 2–3 times weekly for 4–8 weeks; off-periods.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze-thaw cycles.
Dosing Protocol
- Initiation: 50–100 mcg per injection; assess tolerance before increasing.
- Target: 100–150 mcg per injection, 2–3 times weekly.
- Frequency: Non-consecutive days (e.g., Mon/Wed/Fri) to mimic pulsatile GnRH release.
- Cycle Duration: 4–8 weeks; off-periods to maintain pituitary sensitivity.
- Timing: Morning administration preferred; rotate sites.
- Break between cycles: Following the cycle (4–8 weeks), a 4–6 week washout period is recommended. The break maintains GnRH receptor sensitivity.
Washout & Cycle Restart
When can I restart?
Following the cycle (4–8 weeks), a 4–6 week washout period is recommended. The break maintains GnRH receptor sensitivity.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: Store at −20 °C in dry, dark conditions.
- Reconstituted: Refrigerate at 2–8 °C; use within 4 weeks; avoid freeze-thaw cycles.
- Allow vials to reach room temperature before opening.
Important Notes
- Limit continuous daily dosing to ≤14 days to avoid receptor desensitization.
Potential Benefits & Side Effects
Potential Benefits:
- Supports endogenous testosterone production via LH stimulation.
- May help maintain testicular volume and function during exogenous testosterone therapy.
- Promotes spermatogenesis and fertility in hypogonadotropic hypogonadism with pulsatile regimens.
- Generally well-tolerated; occasional mild injection site reactions.
- Potential for transient headache or flushing shortly after injection.
Potential Side Effects:
- Occasional mild injection site reactions (redness, itching, swelling).
- Potential for transient headache or flushing.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Hypogonadism with chronic use (downregulation)
Continuous (non-pulsatile) GnRH administration leads to receptor downregulation → iatrogenic hypogonadism. Therapeutically used as 'chemical castration' in prostate cancer.
📄 NEJM 1986References
- GnRH Agonists: Gonadorelin, Leuprolide, Nafarelin — Pharmacology and Clinical Applications — GnRH agonists: gonadorelin, leuprolide, and nafarelin – pharmacology and clinical applications
View Source - Gonadorelin Injection: Routes and Indications — Mayo Clinic — Gonadorelin injection: routes of administration and indications
View Source - GnRH Analogues: Pulsatile vs. Continuous Effects on FSH/LH (PMC) — GnRH analogues: pulsatile vs. continuous effects on FSH/LH
View Source - Gonadotropin Therapy in Hypogonadotropic Hypogonadism — Spermatogenesis and Fertility — Gonadotropin therapy in hypogonadotropic hypogonadism – spermatogenesis and fertility
View Source - Pulsatile Gonadorelin Pump Induces Spermatogenesis in Congenital HH (PMC) — Pulsatile gonadorelin pump induces spermatogenesis in congenital HH
View Source
Recommended Supplements
CoQ10 (Ubiquinol)
Folate (5-MTHF)
Omega-3 (DHA)
External Sources & Regulatory Status
Regulatory Approvals
Factrel® · LH/FSH diagnostic (1973)
Diagnostic / Infertility
FDA + EMA approved
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →